Biologic therapies have helped significantly improve outcomes and quality of life for patients with psoriasis. With several IL-17 and IL-23 inhibitors now available, choosing between biologics often depends on the dermatologist’s experience, the patient’s needs, and potential side effects. Hear Dr. Robert Gniadecki, a Professor of Dermatology and the Director of the Division of Dermatology at the University of Alberta, discuss these treatment options and best practices for therapeutic decision-making.